Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies.
Immunization using the AMA1–RON2 complex of this technology represents a candidate for an effective malaria vaccine against multiple Plasmodium species.
Collaborative Research and Licensing Opportunity: Inhibition of host heme oxygenase-1 as an adjunctive treatment to improve the outcome of conventional antibiotic chemotherapy of Mycobacterium tuberculosis (Mtb) infection.
Inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control.
Collaborative Research and Licensing Opportunity: CD300b expression exacerbates endotoxemia and septic peritonitis
In vivo, administration of anti-CD300b antibodies protects animals from septic shock, due to a reduce level of pro-inflammatory cytokines but subsequent increase in the anti-inflammatory cytokine, IL-10.
Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical models and is undergoing clinical trial evaluation.Immunization with the nucleic acid ZIKV vaccine candidate results in production of noninfectious virus like particles (VLPs) made of ZIKV proteins.These ZIKV VLPs elicit an immune response which includes neutralizing antibodies to ZIKV.
Collaborative Research and Licensing Opportunity: Small Molecule Imaging Of Fungi By Positron Emission Tomography Scanning
The calcofluor derivatives disclosed in the patent application may be utilized as imaging agents specific for fungal infections and could potentially become a standard, non-invasive procedure in the work-up of immunocompromised patients with lung infections.
Collaborative Research and Licensing Opportunity: Synergistic Internal Ribosomal Entry Site (IRES) - MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Available technology comprises live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines.
Collaborative Research and Licensing Opportunity: A bivalent conjugate vaccine for Malaria and Typhoid prophylaxis
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response against Salmonella typhi Vi polysaccharide (ViP).
Collaborative Research and Licensing Opportunity: Polyvalent Influenza Virus-Like Particles (VLPs) and Their Use as Vaccines
This virus-like particle (VLP) vaccine technology for influenza viruses may be utilized for the development of an universal influenza virus vaccine.
Collaborative Research Opportunity: Use of Roseomonas species to treat eczematous (atopic dermatitis) skin disease
Scientists at NIAID have developed a method of treating or preventing atopic dermatitis via the topical application of selected probiotic strains of gram-negative Roseomonas mucosa bacteria.